Dose-finding Study and Pharmacogenomic Analysis of Fixed-rate Infusion of Gemcitabine, Irinotecan and Bevacizumab in Pretreated Metastatic Colorectal Cancer Patients

Overview

Journal Br J Cancer

Specialty Oncology

Date 2010 Oct 14

PMID 20940716

Citations 7

Authors

A Abajo

J Rodriguez

N Bitarte

R Zarate

V Boni

M Ponz

A Chopitea

E Bandres

J Garcia-Foncillas

Affiliations

Soon will be listed here.

Abstract

Background: To determine the dose-limiting toxicity (DLT), maximum tolerated dose, recommended dose (RD) and preliminary evidence of activity of escalating doses of irinotecan (CPT-11) fixed-dose-rate infusional gemcitabine (FDR-GMB) and bevacizumab in pretreated metastatic colorectal cancer (mCRC) patients. Pharmacogenomic analysis was performed to investigate the association between VEGF single-nucleotide polymorphisms and clinical outcome.

Patients And Methods: A total of 89 mCRC patients were recruited in a two-step study design; 28 were included in the dose-finding study and 59 in the pharmacogenomic analysis. The FDR-GMB of 1000 mg m⁻², bevacizumab 5 mg kg⁻¹ and CPT-11 doses ranging from 100 to 160 mg m⁻² were explored. The VEGF protein serum levels were quantified by EIA. Allelic discrimination was performed to genotype polymorphisms in the VEGF gene.

Results: CPT-11 RD was 150 mg m⁻². Diarrhoea and neutropenia were the DLT. After a median follow-up of 42 months, the median time to progression (TTP) and overall survival were 5.2 and 19.9 months, respectively. VEGF levels were significantly correlated with VEGF-2578AA and VEGF-460CC genotypes, and a trend was observed with VEGF+405GG genotype. The presence of any of these genotypes correlated with a longer median TTP (8.8 vs 4.5 months, P=0.04).

Conclusion: The triplet combination tested in this study is effective and well tolerated. A possible predictive role for VEGF gene polymorphisms and baseline VEGF circulating levels is suggested.

Citing Articles

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.

de Rauglaudre B, Sibertin-Blanc C, Fabre A, Le Malicot K, Bennouna J, Ghiringhelli F Ther Adv Med Oncol. 2023; 14:17588359221141307.

PMID: 36601631 PMC: 9806434. DOI: 10.1177/17588359221141307.

Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression.

Sterling Jr C, Marquez-Garban D, Vadgama J, Pietras R Cancers (Basel). 2022; 14(20).

PMID: 36291938 PMC: 9601113. DOI: 10.3390/cancers14205154.

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.

Chionh F, Gebski V, Al-Obaidi S, Mooi J, Bruhn M, Lee C Sci Rep. 2022; 12(1):1238.

PMID: 35075138 PMC: 8786898. DOI: 10.1038/s41598-021-03952-y.

Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

Li M, Kroetz D Pharmacol Ther. 2017; 182:152-160.

PMID: 28882537 PMC: 5785435. DOI: 10.1016/j.pharmthera.2017.08.012.

Bevacizumab: a review of its use in advanced cancer.

Keating G Drugs. 2014; 74(16):1891-1925.

PMID: 25315029 DOI: 10.1007/s40265-014-0302-9.

References

Giantonio B, Catalano P, Meropol N, ODwyer P, Mitchell E, Alberts S . Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25(12):1539-44. DOI: 10.1200/JCO.2006.09.6305. View

Koutras A, Antonacopoulou A, Eleftheraki A, Dimitrakopoulos F, Koumarianou A, Varthalitis I . Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J. 2011; 12(6):468-75. DOI: 10.1038/tpj.2011.37. View

Nishio M, Ohyanagi F, Taguch F, Matsuda M, Sato Y, Okumura S . Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer. Lung Cancer. 2005; 48(1):115-9. DOI: 10.1016/j.lungcan.2004.09.006. View

Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2003; 22(2):229-37. DOI: 10.1200/JCO.2004.05.113. View

Bidard F, Tournigand C, Andre T, Mabro M, Figer A, Cervantes A . Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Ann Oncol. 2009; 20(6):1042-7. DOI: 10.1093/annonc/mdn730. View

Kopetz S, Hoff P, Morris J, Wolff R, Eng C, Glover K . Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2009; 28(3):453-9. PMC: 2815707. DOI: 10.1200/JCO.2009.24.8252. View

Burstein H, Chen Y, Parker L, Savoie J, Younger J, Kuter I . VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008; 14(23):7871-7. DOI: 10.1158/1078-0432.CCR-08-0593. View

Mavroudis D, Pappas P, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K . A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ann Oncol. 2003; 14(2):304-12. DOI: 10.1093/annonc/mdg063. View

Rothenberg M . Current status of second-line therapy for metastatic colorectal cancer. Clin Colorectal Cancer. 2004; 4 Suppl 1:S16-21. View

10.

Correale P, Cusi M, Tsang K, Del Vecchio M, Marsili S, La Placa M . Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon.... J Clin Oncol. 2005; 23(35):8950-8. DOI: 10.1200/JCO.2005.12.147. View

11.

Banks R, FORBES M, Kinsey S, Stanley A, Ingham E, Walters C . Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer. 1998; 77(6):956-64. PMC: 2150108. DOI: 10.1038/bjc.1998.158. View

12.

Plunkett W, Huang P, Xu Y, Heinemann V, Grunewald R, Gandhi V . Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995; 22(4 Suppl 11):3-10. View

13.

Maindrault-Goebel F, Louvet C, Andre T, Carola E, Lotz J, Molitor J . Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer. 2000; 35(9):1338-42. DOI: 10.1016/s0959-8049(99)00149-5. View

14.

Kohne C, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E . Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002; 13(2):308-17. DOI: 10.1093/annonc/mdf034. View

15.

Brogan I, Khan N, Isaac K, Hutchinson J, Pravica V, Hutchinson I . Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum Immunol. 2000; 60(12):1245-9. DOI: 10.1016/s0198-8859(99)00132-9. View

16.

Moore Jr D, Pazdur R, Daugherty K, Tarassoff P, Abbruzzese J . Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest New Drugs. 1992; 10(4):323-5. DOI: 10.1007/BF00944189. View

17.

George M, Tutton M, Janssen F, Arnaout A, Abulafi A, Eccles S . VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia. 2001; 3(5):420-7. PMC: 1506210. DOI: 10.1038/sj.neo.7900186. View

18.

Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N . Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004; 96(6):434-42. PMC: 7713993. DOI: 10.1093/jnci/djh075. View

19.

Mani S, Kugler J, Knost J, Sciortino D, Gibbons J, Garcia J . Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Invest New Drugs. 1999; 16(3):275-8. DOI: 10.1023/a:1006100116229. View

20.

Abigerges D, Armand J, Chabot G, Da Costa L, Fadel E, Cote C . Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst. 1994; 86(6):446-9. DOI: 10.1093/jnci/86.6.446. View